Recent Updates
Recently added Catalysts
PHIO Positive Sentiment

Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894

Tuesday, August 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Phio Pharmaceuticals has announced the receipt of a U.S. Notice of Allowance for its compound PH-894, which selectively targets the BRD4 protein. This development is significant for the company's INTASYL gene-silencing technology, which is aimed at treating proliferative and infectious diseases. The allowance marks a key milestone in their ongoing research and development efforts.

Market Sentiment Analysis

POSITIVE FACTORS

  • Phio Pharmaceuticals received a U.S. Notice of Allowance for PH-894.
  • The compound targets the BRD4 protein, indicating potential for innovative treatments.
  • INTASYL technology shows promise in treating proliferative and infectious diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~9 mo
Medium dilution risk
Lead asset
DP CD8 TIL
Phase 1 · HNSCC

Full Press Release Details

PH-894 protection for chemical structure, genetic sequencing and broad application for proliferative and infectious diseases in U.S. King of Prussia, Pennsylvania–(Newsfile Corp. – August 11, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based on its proprietary INTASYL® gene-silencing technology, today announced the receipt of a U.S. Notice of […]
The post Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894 appeared first on Phio Pharmaceuticals .

Frequently Asked Questions

What is PH-894?

PH-894 is a compound developed by Phio Pharmaceuticals that targets the BRD4 protein.

What does the U.S. Notice of Allowance signify?

It signifies that Phio Pharmaceuticals has received approval for the protection of PH-894's chemical structure and application.

What technology does PH-894 utilize?

PH-894 utilizes Phio's proprietary INTASYL gene-silencing technology.

What diseases could PH-894 potentially treat?

PH-894 may be applicable for treating proliferative and infectious diseases.

ShareAdd on Google
Tags: PHIO Viatris Investor Conferences Healthcare Phio Pharmaceuticals PH-894 BRD4 protein INTASYL technology U.S. Notice of Allowance
Last updated: Aug 11, 2026

Biotech snapshot

Cash runway
$13M liquidity · $1M/mo burn
~9 mo
Medium dilution risk
Lead asset
DP CD8 TILPhase 1
HNSCC →